Business Context and Reporting Period
Company: Chemed Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 1998
Business Overview: Chemed operates through three primary segments: Roto-Rooter (plumbing and drain cleaning), Patient Care (hospice and home health), and Service America (retail and service). The company also holds a significant investment in Vitas Healthcare Corporation.
Key Financial Metrics
| Metric (in thousands) | Q1 1998 | Q1 1997 |
|---|---|---|
| Service Revenues and Sales | $88,412 | $77,657 |
| Income from Operations | $3,745 | $4,217 |
| Net Income | $6,251 | $8,487 |
| Diluted EPS (Net Income) | $0.62 | $0.85 |
| Operating Cash Flow | $7,865 | $6,977 |
| Cash and Cash Equivalents (End of Period) | $72,820 | $20,268 |
| Total Debt (Current + Long-term) | $88,136 | N/A |
| Unused Lines of Credit | $119,100 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% year-over-year, driven by growth in all three segments. Roto-Rooter grew 16%, Patient Care grew 15%, and Service America grew 7%.
- Profitability Decline: Net income decreased 26% to $6.25 million. This decline was primarily due to a reduction in investment gains ($6.16 million in 1998 vs. $9.08 million in 1997) and the absence of $1.11 million in income from discontinued operations recorded in 1997.
- Operating Margin Pressure: Operating income from continuing operations fell 11% to $3.75 million. The Roto-Rooter segment saw its operating margin decline from 9.7% to 9.3% due to a shift in sales mix toward lower-margin plumbing and HVAC services.
- Cash Position: Cash and cash equivalents increased significantly to $72.8 million, up from $20.3 million in the prior year, supported by strong operating cash flows and proceeds from investment sales.
Outlook, Risks, and Management Commentary
- Investment in Vitas: Management holds $27 million in redeemable preferred stock of Vitas Healthcare. While Vitas is exploring long-term financing to improve liquidity, Chemed management believes the investment is fully recoverable with no impairment.
- Regulatory Impact: The Patient Care segment faces expected revenue declines due to the Balanced Budget Act of 1997, which reduced Medicare and Medicaid reimbursements. Excluding acquisitions, this segment's revenues declined 2%.
- Liquidity: The company maintains approximately $119.1 million in unused lines of credit. Management considers current liquidity and capital sources satisfactory for foreseeable needs.
- Software Consulting: Operating costs associated with developing software consulting operations contributed to the decline in overall operating income.
Key Facts for Investor Verification
- Verify the sustainability of the 14% revenue growth given the regulatory headwinds in the Patient Care segment.
- Assess the impact of the changing sales mix in the Roto-Rooter segment on future gross margins.
- Monitor the status of Vitas Healthcare's financing efforts and the potential for impairment of Chemed's $27 million investment.
- Confirm the trajectory of operating costs related to the new software consulting operations.
- Review the composition of "Other income - net" to understand the volatility of investment gains versus core operational earnings.